In guinea-pig resident peritoneal macrophages, BN 52021 shifted PAF-stimulated prostacyclin responses without significantly inhibiting the response to A23187. This control supports response-dependent antagonism within the tested assay. [1]
In human platelet-rich plasma, 10 μM BN-52021 given 5 minutes before stimulation reduced aggregation induced by alkyl-PAF or acyl-PAF. The experiment used separate agonist conditions and a separate WEB-2086 comparator. [2]
In rabbit platelet-rich plasma stimulated with 10 nM PAF, parent Ginkgolide B inhibited aggregation with an IC50 of 441.9 ± 37.9 nM (mean ± SD; three independent experiments). The tested natural-source material was reported as 91.2% pure; this is an assay-specific literature result. [3]
Competitive antagonism of PAF-induced rabbit cell aggregation
Cell-based study · Washed platelets and peripheral-blood polymorphonuclear leukocytes (PMNLs) from adult male rabbits (2–4 kg). [1]
BN 52021 shifted PAF concentration–response curves rightward without reducing their maxima. Schild analysis supported competitive antagonism in both preparations; the reported PMNL pA2 was lower than the platelet pA2.
Literature-Reported Treatment Conditions
- Treatment concentration
- Platelets: 10^-7, 10^-6 and 10^-5 M; PMNLs: 10^-6, 10^-5 and 10^-4 M BN 52021.
- Exposure duration
- 1 min pretreatment; aggregation followed to the maximum light-transmission response.
- Method
- Chronolog 540 light-transmission aggregometry at 37°C; PAF concentration–response and Schild analysis.
- Vehicle
- 1% dimethylsulphoxide vehicle comparator.
- Co-treatment
- PAF stimulation; WEB 2086 and L-652,731 were separate comparator antagonists.
- Reported limits
- Purity/lot authentication and a fixed post-PAF observation duration were not reported in the read methods.
Methods and source locations
Compound reported in the paper: Ginkgolide B; Compound label in the paper: BN 52021
Literature BN 52021 experiments; no validation of an Adooq lot.
pp.1226–1229: aggregation Methods, Materials, Figures 1b/2b and Table 2
PAF-induced washed-rabbit-platelet aggregation: Schild analysis; slope 0.90 ± 0.06 (mean ± s.e.mean). — p.1228, Table 2; p.1227, Figure 1b; pp.1226–1228, Methods and Results
PAF-induced rabbit PMNL aggregation: Schild analysis; slope 1.01 ± 0.08 (mean ± s.e.mean). — p.1228, Table 2 and PMNL Results; p.1229, Figure 2b
Weaker antagonism in guinea-pig macrophage prostacyclin production
Cell-based study · Resident peritoneal macrophages from male guinea-pigs (400–500 g); short-term adherent-cell preparation. [1]
BN 52021 antagonized PAF-stimulated prostacyclin production at higher concentrations than needed for rabbit aggregation responses. Its Schild slope differed from unity, preventing a pA2 estimate. A23187-stimulated prostacyclin production was not significantly inhibited.
Literature-Reported Treatment Conditions
- Treatment concentration
- PAF-response experiments: 10^-5, 10^-4 and 10^-3 M BN 52021; A23187 control tested the same BN 52021 concentrations.
- Exposure duration
- 5 min antagonist equilibration at 37°C before PAF; 60 min stimulation.
- Method
- Radioimmunoassay of released 6-oxo-prostaglandin F1α, the prostacyclin metabolite.
- Vehicle
- 5 μL antagonist solution in DMSO per well; control PAF responses shown in Figure 3. Final vehicle percentage is not specified for these wells in the read method.
- Co-treatment
- PAF concentration–response; separate 10 μM A23187 stimulation control.
- Reported limits
- Final DMSO percentage and compound purity/lot authentication are not specified for the adopted assay.
Methods and source locations
Compound reported in the paper: Ginkgolide B; Compound label in the paper: BN 52021
Literature BN 52021 experiments; no validation of an Adooq lot.
pp.1226–1229 macrophage Methods/Results; Figure 3b (p.1230); Tables 2–3 (pp.1228,1231)
PAF-stimulated macrophage 6-oxo-PGF1α generation: Slope differed significantly from unity (P < 0.05); PAF-response curves shifted rightward without reduction of maximal response. — p.1228, Table 2 and footnote 2; pp.1229–1230, macrophage Results and Figure 3b
6-oxo-PGF1α production with 10 μM A23187: Radioimmunoassay; Table 3 values are mean ± s.e.mean, n = 3. This control is separate from the n = 4 Schild estimate. — p.1229, final Results paragraph; p.1231, Table 3
Inhibition of PAF-induced aggregation in human platelet-rich plasma
Cell-based study · Human platelet-rich plasma from healthy volunteers; experiments repeated using at least three different donors. [2]
At 10 μM, BN-52021 reduced platelet aggregation induced by either alkyl-PAF or acyl-PAF. These are functional aggregation responses rather than direct receptor-binding measurements.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM BN-52021.
- Exposure duration
- 5 min pretreatment; aggregation recorded for up to 6 min.
- Method
- Chrono-log platelet aggregometry at 37°C.
- Vehicle
- DMSO stock diluted with saline; final DMSO did not exceed 0.1%.
- Co-treatment
- Separate stimulation with 8 μM alkyl-PAF or 800 μM acyl-PAF. WEB-2086 (10 μM) was a separate comparator, not a combination treatment.
- Reported limits
- BN-52021 purity and lot analysis are not provided in the read methods; no exact inhibition percentage is extracted from the plot.
Methods and source locations
Compound reported in the paper: Ginkgolide B; Compound label in the paper: BN-52021
Functional effects of literature BN-52021 in human PRP.
Human platelet aggregation and Statistics methods; platelet Results; Figure 4C,D,G and caption
PAF-induced human platelet aggregation: Figure 4 traces and bar graph inspected; no curve-derived decimals. Each set used one donor and was repeated with at least three donors. — Figure 4C,D,G (actual plotted agonist labels); Human platelet aggregation and Statistics; Results: PAF homologues induce platelet aggregation
Parent Ginkgolide B potency in rabbit platelet-rich plasma
Cell-based study · Platelet-rich plasma from female White New Zealand rabbits (3–4 kg). [3]
Natural-source parent Ginkgolide B (compound 1; reported purity 91.2%) inhibited PAF-induced aggregation. The measured parent-compound IC50 is kept separate from more potent amide derivative 2.
Literature-Reported Treatment Conditions
- Treatment concentration
- Parent-compound series shown in Figure 3: 50, 100, 200, 400 and 800 nM.
- Exposure duration
- Maximum aggregation response within 5 min after PAF; preincubation duration not specified in Section 4.3.2.
- Method
- AggRAM light-transmission aggregometry at 37°C; nonlinear regression for IC50.
- Vehicle
- Solvent comparator; Figure 3 labels the control as 0.5% DMSO.
- Co-treatment
- 10 nM PAF stimulation. Amide derivatives were separate comparators.
- Reported limits
- Parent pretreatment duration, final solvent percentage for each parent concentration and impurity identities are not specified in the read assay methods.
Methods and source locations
Compound reported in the paper: Ginkgolide B; Compound label in the paper: GB (1)
Assay-specific result for the reported 91.2%-pure parent material; not a lot-independent potency specification.
Sections 4.1, 4.3.1–4.3.2; Table 3; Figure 3 left panel/caption
Inhibition of PAF-induced rabbit PRP aggregation: Table 3 and Figure 3; mean ± S.D. of three independent experiments (Figure 3 caption); PAF 10 nM in Section 4.3.2. — Table 3, GB (1) row; Figure 3 left panel and caption; Sections 4.1 and 4.3.1–4.3.2